Raymond B Mailhot Vega1, Omar Ishaq1, Ann Raldow2, Carmen A Perez1, Rachel Jimenez3, Marielle Scherrer-Crosbie4, Marc Bussiere3, Alphonse Taghian3, David J Sher5, Shannon M MacDonald6. 1. Department of Radiation Oncology, NYU School of Medicine, New York, New York. 2. Radiation Oncology Program, Harvard University, Boston, Massachusetts. 3. Department of Radiation Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts. 4. Cardiovascular Research Center, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts. 5. Department of Radiation Oncology, University of Texas Southwestern Medical Center, San Antonio, Texas. 6. Department of Radiation Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: smacdonald@partners.org.
Abstract
PURPOSE: Cardiac toxicity due to conventional breast radiation therapy (RT) has been extensively reported, and it affects both the life expectancy and quality of life of affected women. Given the favorable oncologic outcomes in most women irradiated for breast cancer, it is increasingly paramount to minimize treatment side effects and improve survivorship for these patients. Proton RT offers promise in limiting heart dose, but the modality is costly and access is limited. Using cost-effectiveness analysis, we provide a decision-making tool to help determine which breast cancer patients may benefit from proton RT referral. METHODS AND MATERIALS: A Markov cohort model was constructed to compare the cost-effectiveness of proton versus photon RT for breast cancer management. The model was analyzed for different strata of women based on age (40 years, 50 years, and 60 years) and the presence or lack of cardiac risk factors (CRFs). Model entrants could have 1 of 3 health states: healthy, alive with coronary heart disease (CHD), or dead. Base-case analysis assumed CHD was managed medically. No difference in tumor control was assumed between arms. Probabilistic sensitivity analysis was performed to test model robustness and the influence of including catheterization as a downstream possibility within the health state of CHD. RESULTS: Proton RT was not cost-effective in women without CRFs or a mean heart dose (MHD) <5 Gy. Base-case analysis noted cost-effectiveness for proton RT in women with ≥1 CRF at an approximate minimum MHD of 6 Gy with a willingness-to-pay threshold of $100,000/quality-adjusted life-year. For women with ≥1 CRF, probabilistic sensitivity analysis noted the preference of proton RT for an MHD ≥5 Gy with a similar willingness-to-pay threshold. CONCLUSIONS: Despite the cost of treatment, scenarios do exist whereby proton therapy is cost-effective. Referral for proton therapy may be cost-effective for patients with ≥1 CRF in cases for which photon plans are unable to achieve an MHD <5 Gy. Published by Elsevier Inc.
PURPOSE:Cardiac toxicity due to conventional breast radiation therapy (RT) has been extensively reported, and it affects both the life expectancy and quality of life of affected women. Given the favorable oncologic outcomes in most women irradiated for breast cancer, it is increasingly paramount to minimize treatment side effects and improve survivorship for these patients. Proton RT offers promise in limiting heart dose, but the modality is costly and access is limited. Using cost-effectiveness analysis, we provide a decision-making tool to help determine which breast cancerpatients may benefit from proton RT referral. METHODS AND MATERIALS: A Markov cohort model was constructed to compare the cost-effectiveness of proton versus photon RT for breast cancer management. The model was analyzed for different strata of women based on age (40 years, 50 years, and 60 years) and the presence or lack of cardiac risk factors (CRFs). Model entrants could have 1 of 3 health states: healthy, alive with coronary heart disease (CHD), or dead. Base-case analysis assumed CHD was managed medically. No difference in tumor control was assumed between arms. Probabilistic sensitivity analysis was performed to test model robustness and the influence of including catheterization as a downstream possibility within the health state of CHD. RESULTS: Proton RT was not cost-effective in women without CRFs or a mean heart dose (MHD) <5 Gy. Base-case analysis noted cost-effectiveness for proton RT in women with ≥1 CRF at an approximate minimum MHD of 6 Gy with a willingness-to-pay threshold of $100,000/quality-adjusted life-year. For women with ≥1 CRF, probabilistic sensitivity analysis noted the preference of proton RT for an MHD ≥5 Gy with a similar willingness-to-pay threshold. CONCLUSIONS: Despite the cost of treatment, scenarios do exist whereby proton therapy is cost-effective. Referral for proton therapy may be cost-effective for patients with ≥1 CRF in cases for which photon plans are unable to achieve an MHD <5 Gy. Published by Elsevier Inc.
Authors: Line B Stick; Jen Yu; Maja V Maraldo; Marianne C Aznar; Anders N Pedersen; Søren M Bentzen; Ivan R Vogelius Journal: Int J Radiat Oncol Biol Phys Date: 2016-12-13 Impact factor: 7.038
Authors: Anthony F Yu; Alice Y Ho; Lior Z Braunstein; Maria E Thor; Katherine Lee Chuy; Anne Eaton; Elton Mara; Oren Cahlon; Chau T Dang; Kevin C Oeffinger; Richard M Steingart; Jennifer E Liu Journal: J Am Soc Echocardiogr Date: 2019-02-28 Impact factor: 5.251
Authors: Robert W Mutter; J Isabelle Choi; Rachel B Jimenez; Youlia M Kirova; Marcio Fagundes; Bruce G Haffty; Richard A Amos; Julie A Bradley; Peter Y Chen; Xuanfeng Ding; Antoinette M Carr; Leslie M Taylor; Mark Pankuch; Raymond B Mailhot Vega; Alice Y Ho; Petra Witt Nyström; Lisa A McGee; James J Urbanic; Oren Cahlon; John H Maduro; Shannon M MacDonald Journal: Int J Radiat Oncol Biol Phys Date: 2021-05-25 Impact factor: 8.013
Authors: Alexander Lin; John H C Chang; Ryan S Grover; Frank J P Hoebers; Upendra Parvathaneni; Samir H Patel; Juliette Thariat; David J Thomson; Johannes A Langendijk; Steven J Frank Journal: Int J Part Ther Date: 2021-06-25